You are here

  • Home
  • Archive
  • Volume 65, Issue 7
  • Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB

Article info

Article menu
Tuberculosis
Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB
Free

Authors

  1. Correspondence to Dr Dick Menzies, Montreal Chest Institute, 3650 St-Urbain, Room K1.24, Montreal, Quebec, Canada H2X 2P4; dick.menzies{at}mcgill.ca
View Full Text

Citation

Aspler A, Long R, Trajman A, et al
Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB
Thorax 2010;65:582-587.

Publication history

  • Received August 7, 2009
  • Accepted March 26, 2010
  • First published July 13, 2010.
Online issue publication 
September 01, 2022

  • Web Only Data thx.2009.125054

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.